Quick Answer
CERO THERAPEUTICS HOLDINGS, INC. reported R&D Expense of $6.32 million for fiscal year 2024.
CERO THERAPEUTICS HOLDINGS, INC. R&D Expense — Annual History
| Fiscal Year | R&D Expense | YoY Change |
|---|---|---|
| 2024 | $6.32M | +726.4% |
| 2024 | $764.2K | -85.6% |
| 2023 | $5.29M | — |
Quarterly R&D Expense
| Quarter Ending | R&D Expense | YoY | QoQ |
|---|---|---|---|
| September 30, 2025 | $2.39M | +34.5% | -13.4% |
| June 30, 2025 | $2.75M | +1.5% | -5.3% |
| March 31, 2025 | $2.91M | +221.7% | +63.9% |
| September 30, 2024 | $1.77M | — | -34.6% |
| June 30, 2024 | $2.71M | +127.5% | +200.3% |
| March 31, 2024 | $904.0K | -49.8% | +18.3% |
| January 31, 2024 | $764.2K | — | -35.9% |
| June 30, 2023 | $1.19M | — | -33.7% |
- CERO THERAPEUTICS HOLDINGS, INC. showed an increase of +726.4% in R&D Expense compared to the prior fiscal year.
- Over the 2023–2024 period, CERO THERAPEUTICS HOLDINGS, INC.’s r&d expense has grown by 19.4% (from $5.29 million to $6.32 million).
- The most recent figure is from CERO THERAPEUTICS HOLDINGS, INC.’s fiscal year 2024 report (Form 10-K), filed with the SEC on April 15, 2025.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: